Z6尊龙凯时

23
Mar 2022
CARsgen 2021 Annual Results: Steady Advancement in Innovative CAR T Products and Technologies
Mar 23, 2022
23
Mar 2022
CARsgen Announces First Patient Enrollment in the Confirmatory Phase II Clinical Trial of CT041 in China
Mar 23, 2022
03
Mar 2022
Claudin18.2 CAR T Cells (CT041) Receives Approval to Initiate A Confirmatory Phase II Clinical Trial for advanced GC/GEJ in China
Mar 03, 2022
21
Feb 2022
CARsgen Therapeutics Opens New U.S. cGMP Facility for CAR T Production
Feb 21, 2022
17
Jan 2022
CARsgen Appoints Richard John Daly as the President of CARsgen Therapeutics Corporation
Jan 17, 2022
10
Jan 2022
CARsgen Announces CT041 CAR T-cell Product Candidate Granted RMAT Designation by the FDA
Jan 10, 2022
13
Dec 2021
CARsgen Presents Updated Research Results on BCMA CAR T-cell Product (CT053) at 2021 ASH Annual Meeting
Dec 13, 2021
15
Nov 2021
CARsgen Announces CAR T-cell Product Candidate CT041 Granted PRIME Eligibility by the EMA
Nov 15, 2021
20
Sep 2021
Appealing Data of CARsgen Therapeutics' CAR-T (CT041) in Advanced Gastric Cancer Presented at ESMO
Sep 20, 2021
31
Jul 2021
CARsgen Expanded Collaboration with Shanghai Cancer Institute to Enhance Scientific and Technological Transformation
Jul 31, 2021
【网站地图】